Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Acceptance for Registration and Market Authorization Application of Recombinant Human Follitropin Alfa Solution for Injection

Time:2025-01-26

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Provision for Impairment of Assets

Time:2025-01-10

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Approval Notice for Clinical Trial

Time:2024-12-19

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Appointment of Vice President of The Company

Time:2024-11-26

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2024 Fifth Extraordinary General Meeting

Time:2024-11-25

Ad hoc announcement pursuant to Art. 53 LR-Joincare Announcement on Appointment of Vice President of The Company

Time:2024-10-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 Fifth Extraordinary General Meeting

Time:2024-10-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Leuprorelin Acetate Microspheres for Injection Passing Consistency Evaluation

Time:2024-10-15

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Approval for the New Indication of Tri-torelin Acetate Microspheres for Injection

Time:2024-10-08

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Change of Board Secretary of the Company

Time:2024-09-27

< 1234...12 >